Vitamin D and primary hyperparathyroidism (PHPT)

Journal of Steroid Biochemistry and Molecular Biology

Volumn 121, Issue 1-2, 2010, Pages 199-203

  Souberbielle, Jean Claude ^a,b,c   Maury, Emilie ^c,d   Friedlander, Gérard ^a,b,c   Cormier, Catherine ^c,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d APHP ^*  (France)

Author keywords

Biological reference values; Parathyroid hormone; Primary hyperparathyroidism; Vitamin D

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; HUMAN; PRIMARY HYPERPARATHYROIDISM; REFERENCE VALUE; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; AGED; BLOOD; BONE; DIET SUPPLEMENTATION; FEMALE; HYPERCALCEMIA; MALE; METABOLISM; MIDDLE AGED; MUTATION; PHENOTYPE;

AGED; BONE AND BONES; CALCITRIOL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; REFERENCE VALUES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 77954815501     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.03.077     Document Type: Article

References (66)

1. Holick M. Vitamin D deficiency. N. Engl. J. Med. 2007, 357(July (3)):266-281.
2. Lundgren E., Hagström E.G., Lundin J., Winnerbäck K., Ross L.J., Ljunghall S., Rastad J. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J. Surg. 2002, 26(August (8)):931-936.
3. Eastell R., Arnold A., Brandi M.L., Brown E.M., D'Amour P., Hanley D.A., Rao D.S., Rubin M.R., Goltzman D., Silverberg S.J., Marx S.J., Peacock M., Mosekilde L., Bouillon R., Lewieki E.M. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):340-350.
4. Silverberg S.J., Lewiecki E.M., Mosekilde L., Peacock M., Rubin M.R. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):351-365.
5. Szabo E., Lundgren E., Juhlin C., Ljunghall S., Akerström G., Rastad J. Double parathyroid adenoma, a clinically nondistinct entity of primary hyperparathyroidism. World J. Surg. 1998, 22(July (7)):708-713.
6. Marcocci C., Cetani F., Rubin M.R., Silverberg S.J., Pinchera A., Bilezikian J.P. Parathyroid carcinoma. J. Bone Miner. Res. 2008, 23(December (12)):1869-1880.
7. Udelsman R., Pasieka J.L., Sturgeon C., Young J.E., Clark O.H. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):366-372.
8. Khan A., Grey A., Shoback D. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):373-381.
9. Bilezikian J.P., Khan A.A., Potts J.T. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):335-339.
10. Clements M.R., Davies M., Fraser D.R., Lumb G.A., Mawer E.B., Adams P.H. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin. Sci. (Lond.) 1987, 73(December (6)):659-664.
11. Christensen S.E., Nissen P.H., Vestergaard P., Heickendorff L., Rejnmark L., Brixen K., Mosekilde L. Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism. Eur. J. Endocrinol. 2008, 159(December (6)):719-727.
12. Silverberg S.J., Shane E., Dempster D.W., Bilezikian J.P. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am. J. Med. 1999, 107(December (6)):561-567.
13. Brown A.J., Dusso A., Slatopolsky.E. Vitamin D. Am. J. Physiol. 1999, 277(August (2 Pt 2)):F157-F175.
14. Henry H.L., Norman A.W. Vitamin D: metabolism and biological actions. Annu. Rev. Nutr. 1984, 4:493-520.
15. Hosoi J., Abe E., Suda T., Kuroki T. Regulation of melanin synthesis of B16 mouse melanoma cells by 1 alpha, 25-dihydroxyvitamin D3 and retinoic acid. Cancer Res. 1985, 45(April (4)):1474-1478.
16. Bolland M.J., Grey A.B., Gamble G.D., Reid.I.R. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 2005, 90(March (3)):1525-1530.
17. Boudou P., Ibrahim F., Cormier C., Sarfati E., Souberbielle J.C. A very high incidence of low 25 hydroxy-vitamin D serum concentration in a French population of patients with primary hyperparathyroidism. J. Endocrinol. Invest. 2006, 29(June (6)):511-515.
18. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., Meunier P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997, 7(5):439-443.
19. Van der Wielen R.P., Löwik M.R., van den Berg H., de Groot L.C., Haller J., Moreiras O., van W.A., Staveren Serum vitamin D concentrations among elderly people in Europe. Lancet 1995, 346(July (8969)):207-210.
20. Harinarayan C.V., Gupta N., Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin. Endocrinol. (Oxf.) 1995, 43(September (3)):351-358.
21. Moosgaard B., Vestergaard P., Heickendorff L., Melsen F., Christiansen P., Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 2005, 63(November (5)):506-513.
22. Rao D.S., Honasoge M., Divine G.W., Phillips E.R., Lee M.W., Ansari M.R., Talpos G.B., Parfitt A.M. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J. Clin. Endocrinol. Metab. 2001, 86(May (5)):2328.
23. Moosgaard B., Vestergaard P., Heickendorff L., Melsen F., Christiansen P., Mosekilde L. Plasma 25-hydroxyvitamin D and not 1,25-dihydroxyvitamin D is associated with parathyroid adenoma secretion in primary hyperparathyroidism: a cross-sectional study. Eur. J. Endocrinol. 2006, 155(August (2)):237-244.
24. Raef H., Ingemansson S., Sobhi S., Sultan A., Ahmed M., Chaudhry M. The effect of vitamin D status on the severity of bone disease and on the other features of primary hyperparathyroidism (pHPT) in a vitamin D deficient region. J. Endocrinol. Invest. 2004, 27(October (9)):807-812.
25. Ozbey N., Erbil Y., Ademoĝlu E., Ozarmaĝan S., Barbaros U., Bozbora A. Correlations between vitamin D status and biochemical/clinical and pathological parameters in primary hyperparathyroidism. World J. Surg. 2006, 30(March (3)):321-326.
26. Kebebew E., Duh O.Y., Clark O.H. Tertiary hyperparathyroidism: histologic patterns of disease and results of parathyroidectomy. Arch. Surg. 2004, 139(September (9)):974-977.
27. Rivkees S.A., el-Hajj-Fuleihan G., Brown E.M., Crawford J.D. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 1992, 75(December (6)):1514-1518.
28. Akerström G., Rudbeerg C., Grimelius L., Bergström R., Johansson H., Ljunghall S., Rastad J. Histologic parathyroid abnormalities in an autopsy series. Hum. Pathol. 1986, 17(May (5)):520-527.
29. Yano S., Sugimoto T., Tsukamoto T., Chihara K., Kobayashi A., Kitazawa S., Maeda S., Kitazawa R. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur. J. Endocrinol. 2003, 148(April (4)):403-411.
30. Brown A.J., Zhong M., Finch J., Ritter C., McCracken R., Morrissey J., Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am. J. Physiol. 1996, 270(March (3 Pt 2)):F454-F460.
31. Arnold A., Shattuck T.M., Mallya S.M., Krebs L.J., Costa J., Gallagher J., Wild Y., Saucier K. Molecular pathogenesis of primary hyperparathyroidism. J. Bone Miner. Res. 2002, 17(Suppl. 2):N30-N36.
32. Lauter K., Arnold A. Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism. J. Bone Miner. Res. 2009, 24(January (1)):102-104.
33. Samander E.H., Arnold A. Mutational analysis of the vitamin D receptor does not support its candidacy as a tumor suppressor gene in parathyroid adenomas. J. Clin. Endocrinol. Metab. 2006, 91(December (12)):5019-5021.
34. Carling T., Kindmark A., Hellman P., Lundgren E., Ljunghall S., Rastad J., Akerström G., Melhus H. Vitamin D receptor genotypes in primary hyperparathyroidism. Nat. Med. 1995, 1(December (12)):1309-1311.
35. Kobayashi T., Sugimoto T., Kobayashi A., Chihara K. Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. Endocr. J. 1998, 45(February (1)):123-125.
36. Corbetta S., Vicentini L., Ferrero S., Lania A., Mantovani G., Cordella D., Beck-Peccoz P., Spada A. Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocr. Relat. Cancer 2005, 12(December (4)):929-937.
37. Tan X., Wen X., Liu.Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J. Am. Soc. Nephrol. 2008, 19(September (9)):1741-1752.
38. Moosgaard B., Christensen S.E., Vestergaard P., Heickendorff L., Christiansen P., Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin. Endocrinol. (Oxf.) 2008, 68(May (5)):707-715.
39. Inoue Y., Kaji H., Hisa I., Tobimatsu T., Naito J., Iu M.F., Sugimoto T., Chihara K. Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyroidism. Endocr. J. 2008, 55(March (1)):57-65.
40. Nordenström E., Westerdahl J., Lindergård B., Lindblom P., Bergenfelz A. Multifactorial risk profile for bone fractures in primary hyperparathyroidism. World J. Surg. 2002, 26(December (12)):1463-1467.
41. Yamashita H., Noguchi S., Uchino S., Watanabe S., Koike E., Murakami T., Fujihira T., Koga Y., Masatsugu T., Yamashita H. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J. Surg. 2002, 26(August (8)):937-941.
42. Carnevale V., Manfredi G., Romagnoli E., De Geronimo S., Paglia F., Pepe J., Scillitani A., D'Erasmo E., Minisola S. Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. Clin. Endocrinol. (Oxf.) 2004, 60(January (1)):81-86.
43. Pradeep P.V., Mishra A., Agarwal G., Agarwal A., Verma A.K., Mishra S.K. Long-term outcome after parathyroidectomy in patients with advanced primary hyperparathyroidism and associated vitamin D deficiency. World J. Surg. 2008, 32(May (5)):829-835.
44. Untch B.R., Barfield M.E., Dar M., Dixit D., Leight G.S., Olson J.A. Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism. Surgery 2007, 142(December (6)):1022-1026.
45. Stewart Z.A., Blackford A., Somervell H., Friedman K., Garrett-Mayer E., Dackiw A.P., Zeiger M.A. 25-Hydroxyvitamin D deficiency is a risk factor for symptoms of postoperative hypocalcemia and secondary hyperparathyroidism after minimally invasive parathyroidectomy. Surgery 2005, 138(December (6)):1018-1025. (discussion 1025-6).
46. Kantorovitch V., Gacad M.A., Seeger L.L., Adams J.S. Bone mineral density increases with vitamin D repletion in patients with coexistent vitamin D insufficiency and primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2000, 85(October (10)):3541-3543.
47. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid.I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J. Clin. Endocrinol. Metab. 2005, 90(April (4)):2122-2126.
48. Grubbs E.G., Rafeeq S., Jimenez C., Feng L., Lee J.E., Evans D.B., Perrier N.D. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?. Surgery 2008, 144(December (6)):852-858. (discussion 858-9).
49. Tucci J.R. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur. J. Endocrinol. 2009, 161(July (1)):189-193.
50. Isidro M.L., Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine 2009, 36(October (2)):305-310.
51. Lips.P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr. Rev. 2001, 22(August (4)):477-501.
52. Chapuy M.C., Preziosi P., Maamer M., Arnaud S., Galan P., Hercberg S., Meunier P.J. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997, 7:439-443.
53. Heaney R. Vitamin D: how much do we need and how much is too much?. Osteoporos Int. 2000, 11:553-555.
54. Nussbaum S., Zahradnik R., Lavigne J., Brennan G., Nozawa-Ung K., Kim L., Keutmann H.T., Wang C., Potts J.T., Segre G. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin. Chem. 1987, 33:1364-1367.
55. Blind E., Schmidt-Gayk H., Scharla S., Flentje D., Fischer S., Göhring U., Hitzler W. Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a mid-region assay. J. Clin. Endocrinol. Metab. 1988, 67:353-360.
56. Endres D., Villanueva R., Sharp C., Singer F. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin. Chem. 1991, 37:162-168.
57. Ratcliffe W., Heath D., Ryan M., Jones S. Performance and diagnostic application of a two-site immunometric assay for parathyrin in serum. Clin. Chem. 1989, 35:1957-1961.
58. Gao P., Scheibel S., D'Amour P., John M., Rao S., Schmidt-Gayk H., Cantor T. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 2001, 16:605-614.
59. Souberbielle J.C., Cormier C., Kindermans C., Gao P., Cantor T., Forette F., Baulieu E.E. Vitamin D status and redefining serum parathyroid hormone reference range. J. Clin. Endocrinol. Metab. 2001, 86:3086-3090.
60. Souberbielle J.C., Fayol V., Sault C., Lawson-Body E., Kahan A., Cormier C. Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin. Chem. 2005, 51:395-400.
61. Souberbielle J.C., Lawson-Body E., Hammadi B., Sarfati E., Kahan A., Cormier C. The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects. J. Clin. Endocrinol. Metab. 2003, 88:3501-3504.
62. Aloia J.F., Feuerman M., Yeh.J.K. Reference range for serum parathyroid hormone. Endocr. Pract. 2006, 12:137-144.
63. Vieth R., Ladak Y., Walfish P.G. Age-related changes in the 25-hydroxyvitamin D versus parathyroid hormone relationship suggest a different reason why older adults require more vitamin D. J. Clin. Endocrinol. Metab. 2003, 88:185-191.
64. Aloia J.F., Talwar S.A., Pollack S., Feuerman M., Yeh.J.K. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am. J. Clin. Nutr. 2006, 84:602-609.
65. Bell N.H., Greene A., Epstein S., Oexmann M.J., Shaw S., Shary J. Evidence for alteration of the vitamin D-endocrine system in blacks. J. Clin. Invest. 1985, 6:470-473.
66. Lepage R., Whittom S., Bertrand S., Bahsali G., D'Amour P. Superiority of dynamic over static reference intervals for intac, midmolecule, and C-terminal parathyrin in evaluating calcemic disorders. Clin. Chem. 1992, 38:2129-2135.